Immunochemical characterization of two antigens recognized by new monoclonal antibodies against human colon carcinoma.
Two different monoclonal antibodies (MAb), called L-D1 and L-C5, were produced after immunization with either intact cells or the methanol phase of glycolipid extracts, respectively, from the same human colon carcinoma line, LoVo. As determined by an antibody-binding radioimmunoassay (RIA) on intact cells, MAb L-D1 and MAb L-C5 were highly reactive with all five colon carcinoma lines tested and with only one out of the 21 cell lines of various tissue origin tested. No reactivity of either MAb was observed with peripheral blood lymphocytes, granulocytes, or erythrocytes from healthy donors of various blood groups. Both MAb were tested in competitive binding experiments with an anti-CEA MAb from our laboratory (CEA 35) and with two previously described anti-colon carcinoma MAb from the Wistar Institute called 1083-17-1A (17-1A) and NS-19.9. In competitive binding experiments, MAb L-D1 was inhibited by MAb 17-1A and reciprocally, whereas MAb L-C5 was not inhibited by any of the other MAb tested. MAb L-D1 precipitated a major protein band with an apparent molecular weight (MW) of 41 kilodaltons (kD); interestingly, MAb 17-1A, which was reported to react with an uncharacterized antigen, precipitated the same protein band of 41 kD. This was confirmed with immunodepletion experiments. Furthermore, after treatment of the colon carcinoma cell line with tunicamycin, both MAb L-D1 and 17-1A precipitated a protein band of 35 kD. This shift of 6 kD suggests that the glycoprotein recognized by these 2 MAb contains two to three N-linked carbohydrate side chains. MAb L-C5 precipitated a group of three to four protein bands ranging from 43 to 53 kD that were not modified by tunicamycin treatment. A preliminary study conducted by using immunoperoxidase labeling on frozen sections of primary colon carcinoma showed that the two new MAb react strongly with these tumors, but also weakly with the normal adjacent mucosa, as did the other anti-colon carcinoma MAb tested.
D000818:Animals; D000911:Antibodies, Monoclonal; D000937:Antigen-Antibody Reactions; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D001667:Binding, Competitive; D002277:Carcinoma / Q000276:immunology* / Q000473:pathology; D002457:Cell Extracts / Q000032:analysis; D002459:Cell Fusion / Q000379:methods; D002460:Cell Line; D003110:Colonic Neoplasms / Q000276:immunology* / Q000473:pathology; D005629:Frozen Sections; D006017:Glycolipids; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007413:Intestinal Mucosa / Q000032:analysis / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D011233:Precipitin Tests; D011863:Radioimmunoassay; D014415:Tunicamycin / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D002457:Cell Extracts; D006017:Glycolipids; D014415:Tunicamycin